Join
Live feed
·
PRReleasevia Quantisnow
Actuate Therapeutics Inc. logo

Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

ByQuantisnow·Wall Street's wire, on your screen.
ACTU· Actuate Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACTU (Actuate Therapeutics Inc.) and more on Quantisnow.